Kalpataru Multiplier Ltd.

Our Bank & DP Click for Online Payment MF portfolio login smart way to invest in gold
Sovereign gold bond(SGB) Exchange trades funds(ETF)
CLOSE

Download our app Kalpataru Share trading from Google/App Store and transfer fund instantly.

Company Profile
more from company profile
HomeMarkets Company Profile Smart Quotes

Smart Quotes

FREDUN PHARMACEUTICALS LTD.

NSE : NABSE : 539730ISIN CODE : INE194R01017Industry : Pharmaceuticals & DrugsHouse : Private
BSE712.25-30.15 (-4.06 %)
PREV CLOSE () 742.40
OPEN PRICE () 727.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4326
TODAY'S LOW / HIGH ()701.25 758.40
52 WK LOW / HIGH () 6501054
NSE
This Company is not listed in NSE
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 1987

Management Info :

Daulat N Medhora - Chairman Fredun N Medhora - Managing Director

Registered Office :

Address : 11th Floor, Tower A,Urmi Estate 95, Ganpatrao Kadam Marg,Lower Parel (West),
Mumbai,
Maharashtra-400013

Phone : 022-40318111

Registrar's Details : Purva Shareregistry (India) Pvt Ltd
Gala No 9,Shiv Shakti, Industrial Estate,Sitaram Mill Comp.,J R Boricha Marg, Lower Parel [E],Mumbai
Listing : BSE
NEWS
04Oct FCCB
Interalia, approved:- 1. Issue of 100 (One Hundred) Unsecured Foreign C..
26Sep FCCB
A meeting of the Board of Directors(the "Board") of Fredun Pharmaceutica..
12Feb Fredun Pharmaceuticals gets orders wor
Fredun Pharmaceuticals has received large orders from Southeast Asian (S..
12Feb Fredun Pharmaceuticals informs about p
Fredun Pharmaceuticals has informed that it enclosed press release title..
19Jan Fredun Pharmaceuticals informs about v
Fredun Pharmaceuticals has informed that it enclosed the Voting Results..
Financials
in Millions
QTR Sep 24 ANNUAL 24
Net Profit42.7399999999999156.24
Gross Profit 75.7699999999999 214.52
Operating Profit 139.52388.98
Net Sales 1073.543490.72
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Astrazeneca Pharma I (BSE)
 7327.65 (14.94%)
M.Cap ( in Cr)
18319.13
Pfizer (BSE)
 5384.25 (10.36%)
M.Cap ( in Cr)
24631.72
Abbott India (BSE)
 29791.25 (1.68%)
M.Cap ( in Cr)
63304.33
Divi's Lab (BSE)
 6059.55 (3.16%)
M.Cap ( in Cr)
160862.01
Senores Pharmaceutic (BSE)
 557.80 (42.66%)
M.Cap ( in Cr)
2568.87
Shareholding Pattern
NON-INSTITUTION 49.48%
PROMOTERS 48.93%
FI/BANKS/INSURANCE 1.59%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%
Mf Holding
Scheme NameHold(%)
No Data Found
ATTENTION INVESTORS

Kalpataru Multiplier Ltd.

Kalpataru is a wishful Divine Tree and in present context a widely Trusted, Time tested and Transparent Share Broker, Mutual Fund Distributor and D.P. of this region.

Mobile Trading App
Mobile Trading IOS App
Call Us 0755-4350141/142/143, 9425008895
Mutual Funds 0755-4276725, 4276726
Email Uskmlho@kalpatarumulti.com

registration nos:

Kalpataru Multiplier Ltd.: SEBI Regn. No. INZ000259437

Registered address: Kalpataru House, 18 Itwara, Bhopal (MP) – 462001

Member Member ID
Bombay Stock Exchange Ltd.(BSE) 3016
National Stock Exchange Ltd. 11152
Multi Commodity Exchange(MCX) 16020

Depository Participant of CDSL DP-ID 12031600

(SEBI Regn No. IN-DP-CDSL-221-2003)

In absence of response/ complaint not addressed to your satisfaction, you may lodge a complaint and reach out to us on:

SMART ODR PORTAL @ https://smartodr.in/login

Copyright © 2016 Kalparatu Multiplier Ltd.
Designed ,Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.
SENSEX78248.13-450.94 (-0.57%)
NIFTY23644.90-168.50 (-0.71%)
Dow Jones 42992.21-333.59 (-0.77%)
Nasdaq 19722.03-298.33 (-1.49%)
CLOSE Disclosure
CLOSE

INFORMATION UNDER THE HEAD SHOULD BE ADDED AS FOLLOWS

  • Sharing of trading credentials - login id & password including OTP's.
  • Trading in leveraged products like options without proper understanding, which could lead to losses.
  • Writing / selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks.
  • Dealing in unsolicited tips through Whatsapp, Telegram, YouTube, Facebook, SMS, Calls, etc.
  • Trading in "Options" based on recommendations from unauthorised / unregistered investment advisors and influencers.
CLOSE SEBI